BSEARTSON LIMITED· Industrial ManufacturingHighNeutral
Announced Mon, 12 Oct, 2026 · 23:21 IST

Artson appoints new Chairman and Additional Non-Executive Director

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.0%Reaction day
₹151.95
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+1.8% vs market
Industrial Products peers, median of 132sector+0.0%+2.0% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.0 pts more than its Industrial Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.0+0.2+1.8+0.0+2.0
Next day
-1.8+0.9-2.7+0.5-2.4
2d
-2.6-0.8-1.8-0.9-1.7
3d
-0.6-0.1-0.6-0.6-0.0
4d
+0.0-1.7+1.8-2.0+2.0
5d
-4.1-4.3+0.2-4.4+0.3
1w
-9.5-7.5-2.0-8.6-1.0
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Industrial Products peers, median of 132Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Artson appointed Mr. Sukumar Hebbar as Additional Director and Chairman, and Ms. Priti Patel as Additional Director, both Non-Executive roles effective 12th October 2026. Mr. Hebbar is currently MD and CEO of Tata Projects with 36 plus years EPC experience. Ms. Patel is Chief Business Transformation Officer at Tata Projects. Both appointments need member approval at the next General Meeting. The Nomination and Remuneration Committee was also reconstituted.

Likely market impact

Brings senior Tata Projects leadership onto the board, potentially strengthening strategic and EPC expertise. Appointments need shareholder approval.